XFORX4 Pharmaceuticals, Inc

Nasdaq x4pharma.com


$ 0.58 $ 0.01 (1.62 %)    

Monday, 01-Jul-2024 15:57:49 EDT
QQQ $ 481.74 $ 2.81 (0.59 %)
DIA $ 391.56 $ 0.33 (0.08 %)
SPY $ 545.33 $ 1.12 (0.21 %)
TLT $ 90.13 $ -1.58 (-1.73 %)
GLD $ 215.59 $ 0.56 (0.26 %)
$ 0.5894
$ 0.61
$ 0.00 x 0
$ 0.00 x 0
$ 0.58 - $ 0.64
$ 0.57 - $ 2.06
4,435,200
na
117.88M
$ 1.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-21-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-19-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-11-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-x4-pharmaceuticals-maintains-5-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains ...

 x4-pharmaceuticals-announced-new-clinical-data-from-its-ongoing-phase-2-trial-of-of-mavorixafor-for-chronic-neutropenia-showing-mavorixafor-was-generally-well-tolerated-and-durably-increased-participants-absolute-neutrophil-counts

100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavo...

 5-biotech-stocks-with-key-catalysts-this-week-merck-intellia-verona-and-more

Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.

 cantor-fitzgerald-reiterates-overweight-on-x4-pharmaceuticals-maintains-5-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $5 pric...

 x4-pharmaceuticals-q1-2024-gaap-eps-026-misses-016-estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-x4-pharmaceuticals-raises-price-target-to-5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises the ...

 fda-approves-x4-pharmaceuticals-mavorixafor-as-first-therapy-for-rare-immunodeficiency-disorder

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immu...

 hc-wainwright--co-reiterates-buy-on-x4-pharmaceuticals-maintains-3-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and maintains ...

 earnings-scheduled-for-march-21-2024

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

 x4-pharmaceuticals-q4-eps-010-beats-015-estimate

X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(...

 b-riley-securities-downgrades-x4-pharmaceuticals-to-neutral-lowers-price-target-to-1

B. Riley Securities analyst Kalpit Patel downgrades X4 Pharmaceuticals (NASDAQ:XFOR) from Buy to Neutral and lowers the pric...

 why-bluebird-bio-shares-are-trading-higher-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from ...